InMed Pharmaceuticals, Inc. (INM)
1.305
+0.02
(+1.16%)
USD |
NASDAQ |
Sep 14, 16:00
1.305
0.00 (0.00%)
After-Hours: 17:34
InMed Pharmaceuticals Enterprise Value : 4.654M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 4.654M |
| September 10, 2026 | 4.760M |
| September 09, 2026 | 4.760M |
| September 08, 2026 | 4.867M |
| September 04, 2026 | 5.134M |
| September 03, 2026 | 4.867M |
| September 02, 2026 | 4.974M |
| September 01, 2026 | 4.814M |
| August 31, 2026 | 4.974M |
| August 28, 2026 | 5.134M |
| August 27, 2026 | 5.401M |
| August 26, 2026 | 5.401M |
| August 25, 2026 | 5.455M |
| August 24, 2026 | 5.401M |
| August 21, 2026 | 5.561M |
| August 20, 2026 | 6.202M |
| August 19, 2026 | 6.256M |
| August 18, 2026 | 5.455M |
| August 17, 2026 | 5.561M |
| August 14, 2026 | 5.615M |
| August 13, 2026 | 5.401M |
| August 12, 2026 | 5.455M |
| August 11, 2026 | 5.561M |
| August 10, 2026 | 5.294M |
| August 07, 2026 | 5.615M |
| Date | Value |
|---|---|
| August 06, 2026 | 5.401M |
| August 05, 2026 | 5.241M |
| August 04, 2026 | 5.722M |
| August 03, 2026 | 5.561M |
| July 31, 2026 | 5.615M |
| July 30, 2026 | 5.775M |
| July 29, 2026 | 6.683M |
| July 28, 2026 | 6.683M |
| July 27, 2026 | 6.522M |
| July 24, 2026 | 6.896M |
| July 23, 2026 | 7.644M |
| July 22, 2026 | 6.629M |
| July 21, 2026 | 5.989M |
| July 20, 2026 | 5.882M |
| July 17, 2026 | 5.882M |
| July 16, 2026 | 6.256M |
| July 15, 2026 | 6.256M |
| July 14, 2026 | 6.095M |
| July 13, 2026 | 6.149M |
| July 10, 2026 | 6.522M |
| July 09, 2026 | 6.629M |
| July 08, 2026 | 6.576M |
| July 07, 2026 | 6.683M |
| July 06, 2026 | 6.362M |
| July 02, 2026 | 6.095M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NervGen Pharma Corp. | 171.34M |
| Milestone Pharmaceuticals, Inc. | 93.24M |
| Clearmind Medicine, Inc. | -12.06M |
| Lexaria Bioscience Corp. | 2.636M |
| Target Group, Inc. (Canada) | 11.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.843M |
| Total Expenses (Quarterly) | 4.843M |
| EPS Diluted (Quarterly) | -1.434 |
| Earnings Yield | -238.8% |
| Normalized Earnings Yield | -218.59 |